Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial

Open access
Cudkowicz, Merit E, Titus, Sarah, Kearney, Marianne, Yu, Hong, Sherman, Alexander, Schoenfeld, David, Hayden, Douglas, Shui, Amy, Brooks, Benjamin, Conwit, Robin, Felsenstein, Donna, Greenblatt, David J, Keroack, Myles, Kissel, John T, Miller, Robert, Rosenfeld, Jeffrey, Rothstein, Jeffrey D, Simpson, Ericka, Tolkoff-Rubin, Nina, Zinman, Lorne, Shefner, Jeremy M·2014·The Lancet Neurology

Abstract

Background Glutamate excitotoxicity may contribute to the pathophysiology of amyotrophic lateral sclerosis (ALS). Studies in ALS animal models show decreased excitatory amino acid transporter 2 (EAAT2) overexpression delays onset and prolongs survival, and that ceftriaxone increases EAAT2 activity in rodent brains. Phase 1, 2, and 3 clinical studies of ceftriaxone for ALS were combined into a three-stage, nonstop study. Methods 514 participants were randomised to ceftriaxone (n=341) or placebo (n=173); 66 participants were enrolled in stages 1 (pharmacokinetics) and 2 (safety) to determine cerebrospinal fluid and blood pharmacokinetics and safety of two dosages: 2 grams and 4 grams/day of ceftriaxone. All participants continued into stage 3 (efficacy) in blinded fashion with participants who began treatment on the discontinued dose analysed in the same group as those on the dose that that was continued. In stage 3, 44 participants previously assigned to 2 or 4 g ceftriaxone in stage 2 received 4 g ceftriaxone; 21 participants assigned to placebo in stage 2 continued on placebo. 448 new participants were randomized in stage 3 to 4 g ceftriaxone or placebo (2:1). Participants, family members and all site staff were blinded to treatment assignment. Computerized randomisation sequence using permuted blocks of 3 was stratified by riluzole use and blocked by site. Participants received 2g ceftriaxone or placebo BID via a central venous catheter (CVC) administered in the home setting by a trained caregiver. To minimize biliary side effects, participants assigned to ceftriaxone also received 300 mg ursodiol BID in a blinded manner; those assigned to placebo received matched placebo capsules BID. The co-primary efficacy outcomes were survival and functional decline, using the slope of scores on the ALS Functional Rating Scale-Revised (ALSFRS-R). The first participant entered the trial on September 4, 2006 (stage 1); the first stage-3 participant entered on June 4, 2009. The trial was stopped in July 2012. Findings During stages 1 and 2, ALSFRS-R functional decline was 0.5076±0.2440 units per month slower in participants taking 4 g ceftriaxone versus those taking placebo (95% CI 0.0196, 0.9956, p=0.0416), yet in stage 3, functional decline differed only by 0.08975±0.07581 units per month (95% CI −0.05919, 0.2387; p=0.2370). No significant differences were seen in stage 3 survival (hazard ratio, 0.904 [95% CI 0.710, 1.152]; p=0.4146). Adverse events rates were higher in the ceftriaxone versus placebo group for gastrointestinal (72% [245/340] vs 56% [97/173]; p=0.0004) and hepatobiliary events (62% [211/340] vs 11% [19/173]; p<0.0001). Add-on ursodiol reduced these events in participants taking ceftriaxone. A significantly larger percentage of ceftriaxone versus placebo participants experienced hepatobiliary serious adverse events (12% [41/340] vs 0% [0/173]). Interpretation Despite promising stage-2 efficacy data, the stage-3 ceftriaxone in ALS study failed to show clinical efficacy. The adaptive design approach allowed for seamless movement from one phase to another obviating the need for multiple grant submissions. CVC use in the home setting was shown to be not only possible, but also safe.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(14)70222-4

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 241

Metadata

Authors
Cudkowicz, M. E., Titus, S., Kearney, M., Yu, H., Sherman, A., Schoenfeld, D., Hayden, D., Shui, A., Brooks, B., Conwit, R., Felsenstein, D., Greenblatt, D. J., Keroack, M., Kissel, J. T., Miller, R., Rosenfeld, J., Rothstein, J. D., Simpson, E., Tolkoff-Rubin, N., Zinman, L., & Shefner, J. M.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2014-11
Volume
13
Issue
11
Pages
1083-1091
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2139560421
Cited by
241
References
2
FWCI
12.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(14)70222-4
The paper
Cudkowicz, M. E., Titus, S., Kearney, M., Yu, H., Sherman, A., Schoenfeld, D., Hayden, D., Shui, A., Brooks, B., Conwit, R., Felsenstein, D., Greenblatt, D. J., Keroack, M., Kissel, J. T., Miller, R., Rosenfeld, J., Rothstein, J. D., Simpson, E., Tolkoff-Rubin, N., . . . Shefner, J. M. (2014). Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(14)70222-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.